Literature DB >> 3974378

Nasopharyngeal carcinoma: an evaluation of 134 patients treated between 1971-1980.

R I Dickson, A D Flores.   

Abstract

An analysis is made of 134 patients with nasopharyngeal carcinoma treated from 1971-1980 at the Cancer Control Agency of British Columbia. Incidence rate for Chinese born in the Orient was 20.5 per 100,000 per year compared to 1.32 per 100,000 for Canadian born Chinese. The Caucasian rate was .19 per 100,000 per year. These figures confirm a 15 times greater incidence of the disease in Chinese born in the Orient over those born in North America. The 86 Chinese patients were noted to have a 10% poorer survival than the 48 Caucasian patients on long-term follow-up. The main factor affecting survival was initial staging. Overall survival rates were 46.3% three year, no evidence of disease (NED) and 38.3% five year NED survival, but when disease was limited to the nasopharynx (T1, T2, N0) they were 73.9% three year NED and 66.6% five year NED survival. One-third of the patients ultimately developed distant metastases below the clavicle. Although lower T and N stage cases had fewer of these, the overall correlation with staging was poor. Female patients showed statistically significant better survival which was not related to better initial staging. They did, however, have 11% fewer eventual distant metastases.

Entities:  

Mesh:

Year:  1985        PMID: 3974378     DOI: 10.1288/00005537-198503000-00007

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  11 in total

1.  Challenges of managing nasopharyngeal carcinoma in a developing country.

Authors:  Olawunmi Fatusi; Olubunmi Akinpelu; Yemisi Amusa
Journal:  J Natl Med Assoc       Date:  2006-05       Impact factor: 1.798

2.  Resection of persistent nasopharyngeal carcinoma.

Authors:  E Yumoto; K Gyo; N Yanagihara
Journal:  Skull Base Surg       Date:  1994

3.  Pathobiology of selected tumors of the base of the skull.

Authors:  L Barnes
Journal:  Skull Base Surg       Date:  1991

4.  Carcinoma of the nasopharynx--comparison of the UICC and Ho clinical staging systems.

Authors:  S L Roth; G Bertram; H Sack
Journal:  Klin Wochenschr       Date:  1989-01-20

5.  Detection of Epstein-Barr virus in a case of undifferentiated nasopharyngeal carcinoma by in situ hybridization with digoxigenin-labelled PCR-generated probes.

Authors:  P Delvenne; B Kaschten; J M Deneufbourg; L Demanez; A Stevenaert; M Reznik; J Boniver
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

Review 7.  Contribution of radiotherapy to function preservation and cancer outcome in primary treatment of nasopharyngeal carcinoma.

Authors:  Anne W M Lee
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

8.  HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans.

Authors:  Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Jonathan B McHugh; Kitrina G Cordell; Avraham Eisbruch; Francis P Worden; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jay Stoerker; Heather Walline; Thomas E Carey; Carol R Bradford
Journal:  Head Neck       Date:  2010-05       Impact factor: 3.147

9.  Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in nasopharyngeal carcinoma via activation of NF-κB pathway.

Authors:  Shu-Peng Chen; Qi Yang; Chan-Juan Wang; Long-Juan Zhang; Yi Fang; Fang-Yong Lei; Shu Wu; Li-Bing Song; Xiang Guo; Ling Guo
Journal:  Mol Cancer       Date:  2014-08-22       Impact factor: 27.401

10.  Use of taxane-containing induction chemotherapy in combination with concurrent chemoradiotherapy in Chinese patients with locally advanced nasopharyngeal carcinoma: a meta-analysis.

Authors:  Rui Tian; Hong Xun Ye; Bao Guo Zhang; Dong Ying Gu; Bing Wen Zhang; Zhi Pan Teng; Mao Yong Jin; Jin Fei Chen; Jian Wei Qi
Journal:  Onco Targets Ther       Date:  2015-11-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.